Investigational drug · Phase 2
APL-9796
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Pulmonary Arterial Hypertension.
Phase 2Last checked: Nov 19, 2026Latest source record: May 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "APL-9796"
First trial start
2025
Apr 9, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "APL-9796", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pulmonary Arterial Hypertension
Approved drugs for the same conditions: High blood pressure (hypertension) · Pulmonary arterial hypertension · Cardiovascular and metabolic · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "APL-9796" as an intervention, largest first.
Apollo Therapeutics LtdIndustry
NCT06846554 · 48 participants (planned) · Start Apr 9, 2025 · Primary completion Aug 30, 2027
Drug: APL-9796; APL-9796 · For: Pulmonary Arterial Hypertension
Sites: London, United Kingdom; Bath, United Kingdom; Cambridge, United Kingdom · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Targeting ZIP12-mediated Zn2+ signaling as a treatment for pulmonary hypertension.
Zhao L, Hopley S, Chen CN, et al. · Sci Transl Med 2026
Also in development for Pulmonary Arterial Hypertension
- INS1009Treprostinil PalmitilPhase 37 trials
Insmed Incorporated · Interstitial Lung Disease, Pulmonary Hypertension, Pulmonary Arterial Hypertension
- IKT-001Phase 32 trials
Inhibikase Therapeutics · Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH)
- RalinepagAPD811Phase 32 trials
United Therapeutics · PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension
- SeralutinibPhase 32 trials
Gossamer Bio USA, Inc. · Pulmonary Arterial Hypertension
- HS235Phase 22 trials
35Pharma Inc., a GSK company · Pulmonary Arterial Hypertension, Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
- NS-863Phase 22 trials
NS Pharma, Inc. · Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD), Pulmonary Arterial Hypertension
- DIAG723Phase 21 trial
Diagonal Therapeutics, Inc. · Hereditary Hemorrhagic Telangiectasia, Pulmonary Arterial Hypertension
- PF-07868489Phase 21 trial
Pfizer · Pulmonary Arterial Hypertension
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.